✅The European Medicines Agency (EMA) is reviewing Valneva’s chikungunya vaccine after serious side effects in older adults. ✅The vaccine, Ixchiq, has been temporarily suspended for adults aged 65 and older. ✅Ixchiq is the world’s first vaccine for chikungunya , developed by Valneva (European) ✅It is a single dose vaccine 📍Chikungunya Disease: ✅Chikungunya disease, is characterised by severe joint pain and impaired mobility, and comes with fever.  ✅Transmission: It is a viral infection (CHIKV) transmitted primarily by the Aedes aegypti and Aedes albopictus mosquitoes and has been described as “an emerging global health threat.” #gs3 #science_and_technology